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Abstract: Small intestinal neuroendocrine neoplasms (SI-
NEN) frequently metastasise to regional lymph nodes, and 
surgery is the mainstay of therapy for such patients. How-
ever, despite the possible use of advanced surgical tech-
niques, the resection of both primary and locoregional 
diseases is not always attainable. Intestinal and multi-
visceral transplantation has been performed in a small 
number of patients with conventionally nonresectable, 
slow-growing tumours threatening the mesenteric root 
but has remained controversial. The use of donor skin 
in “sentinel flaps” in transplantation theoretically offers 
advantages in tailoring immunosuppression and moni-
toring for rejection. We represent (with extended follow-
up) the first case of a patient with inoperable extensive 
mesenteric metastases from SI-NEN, who underwent neo-
adjuvant peptide receptor radionuclide therapy before a 
modified multivisceral transplant with a concomitant vas-
cularised sentinel forearm flap. At 48 months after trans-
plantation, our patient remained at full physical activity 
with no evidence of disease recurrence on either tumour 
biochemistry or radiological imaging.
Keywords: multivisceral; neoplasm; neuroendocrine; 
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Introduction
Neuroendocrine neoplasms (NEN) represent the common-
est type of small intestinal (SI) tumours [1, 2]. Despite their 
relative indolence in terms of survival time compared to 
SI adenocarcinomas, SI-NEN display a strong predilec-
tion for nodal and distant metastasis, namely to the 
mesentery and the liver, respectively. Indeed, although 
the majority of SI-NEN are low-grade, well-differentiated 
entities, institutional case series have demonstrated that 
the identification of regional lymph node metastases at 
initial presentation may approach 90% [3]. Accordingly, 
the surgical intervention for disease control often encom-
passes the extirpation of locoregional disease and also 
the resection of hepatic deposits if present and surgery is 
recognised as the cornerstone in therapeutic strategy in 
patients with resectable disease [4, 5].
The aggressive surgical management of regional 
deposits is mandated in patients with extensive mes-
enteric spread, given the risks of intestinal obstruction 
and encasement of superior mesenteric vessels causing 
intestinal ischaemia. Although several complex methods 
have been developed to render previously unresectable 
tumours (i.e. those in apposition to the coeliac and supe-
rior mesenteric vessels or with retroperitoneal extension) 
amenable to surgery, such as ultrasound-guided superior 
mesenteric vein stenting [6], free dissection of the supe-
rior mesenteric artery and vein at the inferior pancreatic 
border [7] and multivisceral ex vivo autotransplantation 
[8, 9], many patients still suffer from unresectable disease.
The relatively newly embraced concept of “trans-
plantation oncology” has occupied a small albeit highly 
controversial role in intra-abdominal tumours, including 
NEN. Orthotopic liver transplantation is an increasingly 
accepted option in highly selected patients with NEN 
*Corresponding author: Andrea Frilling, Department of Surgery 
and Cancer, Imperial College London, Hammersmith Hospital, 
Du Cane Road, London, W12 0HS, UK, Phone: +44 203 133 210, 
Fax: +44 203 132 037, E-mail: a.frilling@imperial.ac.uk
Ashley K. Clift and Harpreet S. Wasan: Department of Surgery and 
Cancer, Imperial College London, London, UK
Henk Giele and Anil Vaidya: Department of Plastic and 
Reconstructive Surgery, Oxford University NHS Trust, Oxford, UK
Srikanth Reddy, Rubens Macedo and Peter Friend: Oxford 
Transplant Centre, Oxford University NHS Trust, Oxford, UK
Adil Al-Nahhas: Department of Nuclear Medicine, Imperial College 
London, London, UK
Gabriel E. Gondolesi: Instituto de Trasplante Multiorgano, 
Fundacion Favaloro, Buenos Aires, Argentina
Rodrigo M. Vianna: Miami Transplant Institute, University of Miami/
Jackson Memorial Hospital, Miami, FL, USA
 Open Access. © 2017 Clift A.K. et al., published by De Gruyter.  This work is licensed under the Creative Commons Attribution- 
NonCommercial-NoDerivatives 4.0 License. Unauthenticated
Download Date | 1/4/18 1:05 PM
248      Clift et al.: Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation
metastatic to the liver [10], with recent reports inferring 
outcomes similar to those observed in hepatocellular 
carcinoma [11, 12]. Experience with SI and multivisceral 
transplantation (MVT; with or without the liver) for slow-
growing intra-abdominal tumours such as NEN threat-
ening the mesenteric root is limited, although outcomes 
associated with allografts containing the SI in general 
appear to be improving [13, 14]. A number of small case 
series including patients with NEN have been reported, 
predominantly from Scandinavian centres (Table  1) [11, 
15–18]. Lastly, a relatively new approach in transplantation 
surgery is the vascularised sentinel forearm flap (VSFF) 
notably used in facial transplantation. A VSFF comprises 
a skin allograft obtained from the same donor as another 
composite tissue graft and enables the monitoring for 
immune rejection via monitoring the transplanted area 
on the recipient’s forearm [19, 20]. Briefly, the theoretical 
basis of using a VSFF is that the appearance of a rash on 
the graft may indicate a rejection reaction suggestive of 
concomitant rejection of the “primary” graft, in this case, 
the intra-abdominal allograft. The careful monitoring of 
this sentinel site has obvious ramifications on immuno-
suppression and may accordingly permit the tailoring of 
immunosuppressive regimens.
Here, we present the extended follow-up data for a 
patient with SI-NEN with unresectable bulky mesenteric 
metastases managed with peptide receptor radionuclide 
therapy (PRRT) before undergoing combined modified 
liver-free MVT (MMVT) and a VSFF from the same donor. 
The initial report on this patient was published by our 
group in 2015 [21]. This is the first case of its type to dem-
onstrate the use of PRRT as a neoadjuvant concept in 
MMVT and also to implement the use of a VSFF as a tool 
for proactive monitoring of immunosuppression in MMVT 
for a NEN.
The case – initial investigations
Our male patient presented at age 44  with haematuria 
and intermittent abdominal pain in 2009. There were no 
other symptoms or any significant previous medical or 
family history. A standard computed tomography (CT) 
scan of the abdomen was performed, which demonstrated 
a complex and partially calcified left-sided renal cyst, 
and also identified within the mesentery a suspicious 
10 × 9 × 6 cm heterogeneously enhancing mass. The latter 
was subjected to ultrasound-guided biopsy, in which his-
topathology confirmed to be a well-differentiated grade 1 
(Ki-67 <1%) NEN with clear expression of the archetypal 
neuroendocrine markers synaptophysin and chromogra-
nin A (CgA) evident on immunohistochemical analysis. 
Subsequent routine NEN-specific biochemistry included 
serum CgA and chromogranin B (CgB) and urinary 
5-hydroxyindoleacetic acid (5-HIAA) in 24  h urine  – all 
were markedly elevated relative to reference ranges: 
395  pmol/L (0–60  pmol/L), 349  pmol/L (0–150 pmol/L) 
and 643 μmol/L (0–40 μmol/L), respectively.
The patient subsequently underwent imaging with 
68Ga-DOTATATE positron emission tomography (PET)/CT, 
which demonstrated marked radiotracer uptake in the 
aforementioned mesenteric mass [standard uptake value 
(SUV) = 27] and in a lymph node in the aortocaval groove 
(SUV = 10). Thereafter, after multidisciplinary and patient 
discussion, it was decided that the patient would undergo 
Table 1: Overview of previously published experience with multivisceral transplantation for neuroendocrine tumours.
Author (year)   Cohort size 
(NEN)
  Percentage with 
liver metastases
  Primary tumour 
location/type
  Recurrence data   Survival data
Tzakis et al. 
(2012) [8]
  2  N/S   ‘Carcinoid’, VIPoma   24-months post-transplant in 
1 patient
  Death of recurrent disease 
at 24-months in 1 patient
Olausson et al. 
(2007) [15]
  5  100%   Pancreas   25-months and 48-months 
post-transplant in 1 patient 
each, respectively
  2 deaths within 4-months 
post-transplant; 1 death at 
27 months post-transplant
Gedaly et al. 
(2011) [11]
  13  100%   N/S   23% at 1-year, 50% at 3-years, 
and 68% at 5-years, post-
transplant
  80% overall survival at 
1-year, 64% at 3-years, 
48% at 5-years
Mangus et al. 
(2013) [16]
  4  100%   Insulinoma, gastrinoma, 
‘carcinoid’, VIPoma
  10-months and 23-months 
post-transplant in 1 patient 
each, respectively
  1 death at 10 months 
post-transplant
Varkey et al. 
(2013) [17]
  6  100%   Pancreas   100%   67% at 2 years
NEN, neuroendocrine neoplasms; N/S, not specified; VIPoma, vasoactive intestinal peptide-oma.
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an exploratory laparotomy in April 2010. This identified 
a stage IV (i.e. extending retroperitoneally) tumour bulk, 
which was circumferentially encasing the mesenteric 
vessels (Figure  1). Meticulous intraoperative exploration 
and ultrasound elucidated several additional, mostly sub-
centimetre, lymph nodes scattered through the mesentery 
close to the ileum but no evidence of hepatic metastases.
On a multicentre, multidisciplinary team discussion 
of therapeutic strategy in this conventionally unresectable 
tumour, the option of MMVT was raised and the patient 
was referred to the Oxford Transplant Centre for formal 
review with regard to possible intestinal transplantation.
Clinical management
Given the setting of unresectable, metastatic disease 
from a low-grade NEN, the patient received four cycles 
of PRRT with 177Lu-DOTATATE. Each cycle was adminis-
tered after 12-week intervals with a cumulative radiation 
dose of 28 GBq, with no adverse effects associated with 
treatment. Standard nephroprotective amino acid infu-
sions were administered. Post-PRRT 68Ga-DOTATATE PET/
CT in February 2013 did not identify any additional sites 
of disease or progression in size of the previously identi-
fied lesions, but the SUV had increased in both the mes-
enteric bulk and the aortocaval node (Figure 2). Tumour 
biochemistry values had also increased throughout PRRT, 
with post-PRRT CgA and CgB results of 2200 pmol/L (ini-
tially 395 pmol/L) and 450 pmol/L (initially 349 pmol/L), 
respectively.
The patient underwent MMVT with VSFF at the Oxford 
Transplant Centre in March 2013. During operation, the 
mesenteric mass was noted to now involve both the duo-
denum and the pancreas, but there was still no evidence 
of liver metastases. As part of the MMVT, the stomach, 
pancreas, spleen, SI and right and transverse colon were 
exenterated, and the aortocaval lymph node was resected. 
The donor thoracic aorta was used to construct a “jump” 
graft from the recipient thoracic aorta to act as an arterial 
supply to the multivisceral graft. The venous return for the 
graft was constructed by means of a portal-portal anasto-
mosis. A temporary ileostomy was formed.
The VSFF was retrieved from the same donor and 
comprised a 10 × 5 cm elliptoid composite skin island flap 
Figure 1: Bulky mesenteric lymph node metastases as observed at 
laparotomy.
Mesenterial
lymph node
metastases  
Aorto-caval
lymph node
metastasis  
Figure 2: Pretreatment 68Ga-DOTATATE PET imaging clearly demon-
strating pathological radiotracer uptake corresponding to mesen-
teric metastases and also a lymph node metastasis in the aortocaval 
groove.
Unauthenticated
Download Date | 1/4/18 1:05 PM
250      Clift et al.: Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation
derived from the territory overlying the radial artery, with 
subcutaneous tissues, fascia, cephalic vein, lateral cuta-
neous nerve and the radial artery with venae comitantes. 
In the recipient, an incision under a tourniquet was made 
over the ulnar artery territory of the left arm (nondomi-
nant) and deepened to the artery and its venae comitantes. 
The VSFF was flushed with a cold preservative solution 
immediately after retrieval, transported without freez-
ing and ultimately revascularised with an anastomosis 
between the donor’s radial artery and the recipient’s ulnar 
artery on the left arm. The venous outflow for the VSFF 
was established by the connection of donor and recipient 
venae comitantes and anastomosis between the donor’s 
cephalic vein and the recipient’s basilic vein. Lastly, the 
donated lateral cutaneous nerve was coapted to a branch 
of the recipient’s medical cutaneous nerve.
Regarding immunosuppression, the reperfusion of 
transplanted organs was covered with 500 mg methylpred-
nisolone, and induction immunosuppression included 
30 mg intravenous alemtuzumab (Campath) within 6 h of 
reperfusion, with a second dose 24  h later. Initial main-
tenance immunosuppression used tacrolimus with target 
trough levels between 8 and 12 ng/mL. The immediate 
postoperative course was uneventful.
The histopathological analysis of the resected tumour 
confirmed a well-differentiated, grade 1, multifocal SI 
NEN (7 tumours up to 11 mm in size) with attendant large 
mesenteric lymph node metastases up to 120 mm in size 
encasing the mesenteric vessels. Disease stage was con-
firmed as pT3N1M0L1V0R0 using the ENETS/WHO criteria 
[22]. Immunohistochemical analyses again demonstrated 
strong expression of chromogranin and synaptophysin, 
focal expression of CK19 and no expression of glucagon, 
insulin, gastrin, and somatostatin.
Two months after transplantation, the patient under-
went a biopsy of his VSFF due to a maculopapular rash 
suggestive of rejection. The diagnosis of acute rejection 
was made in accordance with the Banff 2007 Working 
Classification of Skin-Containing Composite Tissue Allo-
graft Pathology classification [23]. Endoscopy with intes-
tinal biopsy was performed, which demonstrated no 
evidence of rejection in the abdominal organ graft. There-
fore, the patient was treated with three 500 mg doses of 
methylprednisolone and topical tacrolimus cream, with 
which the rash resolved completely. A daily dose of 10 mg 
oral prednisolone was added to the patient’s maintenance 
immunosuppression regimen.
The patient successfully underwent an uncompli-
cated reversal of his ileostomy in January 2014, and on 
his last follow-up 48  months after transplantation, he 
remained on full enteral nutrition with a stable weight 
and at full physical activity. His NEN-related serum (CgA 
and CgB) and urine (5-HIAA) biochemical markers nor-
malised after transplantation and have remained within 
reference ranges throughout follow-up. Furthermore, 
routine  follow-up imaging with magnetic resonance 
imaging (MRI) or CT every 6 months and 68Ga-DOTATATE 
PET/CT annually have yet to identify any evidence of 
disease recurrence.
Discussion
Contrary to the increasingly accepted role within the 
armamentarium for liver transplantation in metastatic 
gastrointestinal NEN, the use of multivisceral allografts 
attracts considerably more controversy. Although initial 
results with the former were disappointing, the devel-
opment of strict patient selection criteria and advances 
in immunosuppression have resulted in favourable out-
comes that are not significantly inferior to those observed 
in hepatocellular carcinoma [10, 24]. Five-year overall sur-
vival after orthotopic liver transplantation for metastatic 
NEN may reach 90% in recent case series, justifying its 
use as a well-timed (i.e. not a “last resort”) intervention in 
carefully selected patients with nonresectable liver metas-
tases [4]. Furthermore, recent evidence has suggested a 
significant benefit to liver transplantation over nontrans-
plant techniques [25]. Nevertheless, 5-year recurrence 
rates may range between 50% and 90% [12, 26–28], which 
highlights the known difficulties with the insidiously pro-
gressive behaviour of low-grade NEN and also the neces-
sity of novel strategies facilitating long-term control both 
neoadjuvant and adjuvant in nature.
Experience with intestinal transplantation and MVT 
in general is steadily growing, with reported indications 
including abdominal catastrophes and slow-growing 
intra-abdominal tumours, such as NEN. As aforemen-
tioned, this arena within the realm of transplant oncology 
is highly debated due to disparities in outcomes from dif-
ferent centres. The report by Gedaly et  al. [11] described 
the use of MVT in 13 patients with NEN (primary tumour 
origin not clearly stated) associated with 1-, 3- and 5-year 
survival of 80%, 64% and 48%, respectively, whereas in 
a series of 10 NEN patients with liver metastases treated 
at Indiana University over 8  years, an overall survival 
rate of 80% was attained (personal communication [16]). 
A more cautious outlook has been advocated by Varkey 
et  al. [17] in their report of 6 patients with metastatic 
pancreatic NEN, demonstrating a 67% overall survival at 
2 years. With small sample sizes, variation in the quality 
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of documentation in case reports/series, and different 
primary tumour sites, the evidence regarding MVT/MMVT 
for NEN is far from conclusive. Of the approximately 30 
cases of intestinal transplantation/MVT for NEN reported, 
to our knowledge, none have clearly detailed the proce-
dures and outcomes specifically in SB NEN.
Our strategy in this patient centred on four facets:
1. Use of PRRT as a neoadjuvant modality,
2. Radical removal of a classically nonresectable tumour,
3. Restoration of abdominal anatomy and physiology 
with a multivisceral graft, and
4. Use of a second soft-tissue graft from the donor to aid 
posttransplant management.
The use of PRRT in metastatic, unresectable, low-to- 
intermediate grade NEN that exhibit high expression of 
somatostatin receptors may attain tumour response rates 
of approximately 33% [29–31]. There have also been a 
small number of reports in which PRRT has been used as 
a neoadjuvant therapy in NEN, specifically to attempt to 
downsize tumours and render them resectable [32–35]. To 
our knowledge, our report is the first to report the use of 
PRRT as a neoadjuvant therapy specifically in transplan-
tation. A major concern in our patient was that, despite 
the lack of evidence of hepatic disease on morphologi-
cal and functional imaging, micrometastases not detect-
able with these methods may have existed and could 
have subsequently manifested throughout a period of 
immunosuppression. Indeed, currently available gold-
standard imaging methods significantly understage 
true disease burden by up to 50% [36]. Given the strong 
avidity of this patient’s disease for somatostatin receptor-
targeted imaging tracers, the patient was offered PRRT 
with 177 Lu-DOTATATE before radical treatment with an 
aim to treat/stabilise the main tumour bulk and eradicate 
microdisease. An “all-in-one” approach to transplanta-
tion avoided the risks of managing an ultra-short gut with 
a high output stoma, plus deterioration in liver function 
with total parenteral nutrition that would have presented 
if we had proceeded with intestinal exenteration with 
transplantation on a later date.
The theoretical benefits of a sentinel marker in solid-
organ transplantation include the noninvasive monitor-
ing of immunosuppression with possible ramifications 
on preventing rejection and avoiding the morbidity asso-
ciated with excessive immunosuppression. Our rationale 
for concomitant transplantation of a VSFF was to aid the 
clinical team in distinguishing between possible causes 
of posttransplant bowel dysfunction should they arise, 
specifically infective causes or an immunological rejec-
tion, which would be characterised by the lack of and 
presence of a rash, respectively. Although the histopatho-
logical appearances of both phenomena may be similar, 
the treatments for each are obviously different. The use 
of a VSFF has been documented in facial transplantation 
[37]. The usefulness of skin more generally as an immu-
nological tool has also been reported in abdominal wall 
transplantation, where it may serve as an immune modu-
lator resulting in improved graft survival, lower rejection 
rates, and lower rates of incorrectly diagnosed rejection in 
patients receiving solid-organ transplants and abdominal 
wall transplants [38].
In conclusion, this case represents a truly novel 
approach to the treatment of metastatic SI NEN due to its 
unique integration of several treatment concepts. Given 
the favourable outcome documented so far, specifically a 
lack of both biochemical and radiological disease recur-
rence and that the patient remains at full physical activ-
ity at 4 years of follow-up, we believe that this approach 
could be used in other, strictly selected patients in the 
future.
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Reviewers’ Comments to Original Submission 
Reviewer 1: anonymous
May 02, 2017
Reviewer Recommendation Term: Revise with Major Modification
Overall Reviewer Manuscript Rating: N/A
Custom Review Questions Response
Is the subject area appropriate for you? 3
Does the title clearly reflect the paper’s content? 4
Does the abstract clearly reflect the paper’s content? 4
Do the keywords clearly reflect the paper’s content? 2
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 3
How comprehensive and up-to-date is the subject matter presented? 3
How adequate is the data presentation? 2
Are units and terminology used correctly? 3
Is the number of cases adequate? 3
Are the experimental methods/clinical studies adequate? 3
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 4
Please rate the practical significance. 2
Please rate the accuracy of methods. 3
Please rate the statistical evaluation and quality control. 3
Please rate the appropriateness of the figures and tables. 1 - Low/No
Please rate the appropriateness of the references. 4
Please evaluate the writing style and use of language. 3
Please judge the overall scientific quality of the manuscript. 3
Are you willing to review the revision of this manuscript? Yes 
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Comments to Authors:
This manuscript represents an update of a case-report previously published in 2015. The manuscript depicts some interesting Points 
(i.e. the follow-up after two years without evidence of relapse) and describes an infrequent clinical course and therefor is potentially 
publishable. 
However, the figures are exactly the same as used in the first publication of this case-report and are redundant. More interesting would be 
to show intraoperative photos or ones of the VSFF!!! 
Minor points:  
What is the reason for the delay between diagnosis (2009) and initial laparotomy (April 2010) 
The language and style needs revision
Reviewer 2: anonymous
Apr 16, 2017
Reviewer Recommendation Term: Reject 
Overall Reviewer Manuscript Rating: 10
Custom Review Questions Response
Is the subject area appropriate for you? 5 - High/Yes
Does the title clearly reflect the paper’s content? 3
Does the abstract clearly reflect the paper’s content? 3
Do the keywords clearly reflect the paper’s content? 3
Does the introduction present the problem clearly? 3
Are the results/conclusions justified? 3
How comprehensive and up-to-date is the subject matter presented? 3
How adequate is the data presentation? 3
Are units and terminology used correctly? 3
Is the number of cases adequate? N/A
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 3
Does the reader get new insights from the article? 1 - Low/No
Please rate the practical significance. 2
Please rate the accuracy of methods. N/A
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 2
Please rate the appropriateness of the references. 3
Please evaluate the writing style and use of language. 3
Please judge the overall scientific quality of the manuscript. 1 - Low/No
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
There are no new informations compared to the article from 2015 (Modified Liver-free Multivisceral Transplantation for a Metastatic Small 
Bowel Neuroendocrine Tumor: A Case Report), even the images are completely the same. I cannot see the necessity to publish the case 
report again.
Reviewer 3: Klaus-Martin Schulte
Jun 20, 2017
Reviewer Recommendation Term: Accept with Minor Revision
Overall Reviewer Manuscript Rating: 80
Custom Review Questions Response
Is the subject area appropriate for you? 3
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Does the title clearly reflect the paper’s content? 5 - High/Yes
Does the abstract clearly reflect the paper’s content? 5 - High/Yes
Do the keywords clearly reflect the paper’s content? 5 - High/Yes
Does the introduction present the problem clearly? 5 - High/Yes
Are the results/conclusions justified? 5 - High/Yes
How comprehensive and up-to-date is the subject matter presented? 5 - High/Yes
How adequate is the data presentation? 4
Are units and terminology used correctly? 5 - High/Yes
Is the number of cases adequate? 2
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 5 - High/Yes
Please rate the practical significance. 4
Please rate the accuracy of methods. N/A
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 4
Please rate the appropriateness of the references. 5 - High/Yes
Please evaluate the writing style and use of language. 4
Please judge the overall scientific quality of the manuscript. 4
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
Thank you for this interesting contribution which can be published as it stands - following some minor corrections only: see attached 
document.
Authors’ Response to Reviewer Comments
Jul 23, 2017
Reviewer comments:  
 
Reviewer #1: 
This manuscript represents an update of a case-report previously published in 2015. The manuscript depicts some interesting Points (i.e. 
the follow-up after two years without evidence of relapse) and describes an infrequent clinical course and therefore is potentially publish-
able.  
However, the figures are exactly the same as used in the first publication of this case-report and are redundant. More interesting would be 
to show intraoperative photos or ones of the VSFF!!!  
Reply: We thank this reviewer for their kind appraisal and finding that our manuscript is potentially publishable. The submitted manuscript 
included the intra-operative image of the bulky mesenteric metastases as visualised at laparotomy, and further images (intra-operative or 
of the VSFF) would surely add to the revised manuscript. However, we regret that these are not available. We also realise that the figures of 
the functional imaging are the same as those in a previous publication. However, we believe that these have a valuable role in this updated 
case report as: 1) Innovative Surgical Sciences undoubtedly has wider target readership than the journal that the original case report was 
published in, and many readers may not have read the first article; and 2) the images clearly demonstrate the challenging presentation of 
this case.  
 
Minor points:  
What is the reason for the delay between diagnosis (2009) and initial laparotomy (April 2010)  
The language and style needs revision  
Reply: The reviewer is indeed correct in identifying this seemingly relatively protracted delay between diagnosis and initial laparotomy. 
This is due to a combination of patient factors (deciding whether or not to pursue the option of aggressive treatment) and multidisciplinary 
discussion regarding the scope for curative management. We have added a short sentence to the revised manuscript to detail this to future 
readers.  
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We do wish to be able to comply with all reviewer comments. However, we humbly believe that the remark to revise language and style is 
somewhat vague and we are unable to identify the specific aspects of the article that the reviewer would like us to restructure or amend. We 
have however, made some language edits as suggested by another reviewer (please see below).  
 
Reviewer #2: 
There are no new informations compared to the article from 2015 (Modified Liver-free Multivisceral Transplantation for a Metastatic Small 
Bowel Neuroendocrine Tumor: A Case Report), even the images are completely the same. I cannot see the necessity to publish the case 
report again.  
Reply: We wish to express our gratitude to this reviewer for their careful consideration of our manuscript. However, we respectfully disagree 
with this reviewer comment as our updated case report has not only prolonged follow-up (which is absolutely essential in any study of neu-
roendocrine tumour disease given their relative indolence as compared to adenocarcinomas), but further evidence of disease control (i.e. 
the patient is still biochemically and radiologically tumour free in a hitherto unresectable and thus incurable tumour). It also has a broader 
discussion of the indications and rationale for this approach. We find that this reviewer comment contrasts with those of the other review-
ers, which were more favourable.  
 
Reviewer #3: 
Thank you for this interesting contribution which can be published as it stands - following some minor corrections only: see attached docu-
ment.  
Reply: We wish to thank this reviewer for their very kind appraisal. Accordingly, we are glad to revise the manuscript according to their sug-
gestions – these have been clearly marked in red in the revised manuscript  
 
Editor comments: more and better documentation regarding the use of the flaps, this could include a picture; information on the function of 
the transplant (like BMI); an overview of the actually used immunosuppression and how this compared to patients without flaps looks like; a 
table on the cases of duodenal or composite transplants in NET or other primary tumors of the duodenum.  
Reply: We thank the Editor for their contributions to reviewing our paper, and for their constructive suggestions. Accordingly, we have added 
a short explanation of the function of the transplant (see the Introduction, end of paragraph 3, marked in red), as well as a table summaris-
ing cases of other small intestinal/composite transplants in NET (now Table 1). Unfortunately, the documentation of immunosuppressive 
regimens used in multivisceral transplantation in NET is not of a high standard across the case reports/series (a contributory factor may be 
the typically ‘mixed’ nature of the study cohorts) and therefore including this data in a meaningful way would be challenging.
Reviewers’ Comments to Revision 
Reviewer 1: anonymous
Jul 24, 2017
Reviewer Recommendation Term: Accept
Overall Reviewer Manuscript Rating: 40
Custom Review Questions Response
Is the subject area appropriate for you? 3
Does the title clearly reflect the paper’s content? 3
Does the abstract clearly reflect the paper’s content? 3
Do the keywords clearly reflect the paper’s content? 3
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 3
How comprehensive and up-to-date is the subject matter presented? 2
How adequate is the data presentation? 3
Unauthenticated
Download Date | 1/4/18 1:05 PM
Clift et al.: Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation      V
Are units and terminology used correctly? 3
Is the number of cases adequate? N/A
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 3
Please rate the practical significance. 2
Please rate the accuracy of methods. 3
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 1 - Low/No
Please rate the appropriateness of the references. 4
Please evaluate the writing style and use of language. 3
Please judge the overall scientific quality of the manuscript. 2
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
After major revision I can accept the paper in the current form
Reviewer 2: anonymous
Aug 01, 2017
Reviewer Recommendation Term: Reject
Overall Reviewer Manuscript Rating: 50
Custom Review Questions Response
Is the subject area appropriate for you? 5 - High/Yes
Does the title clearly reflect the paper’s content? 3
Does the abstract clearly reflect the paper’s content? 4
Do the keywords clearly reflect the paper’s content? 3
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 4
How comprehensive and up-to-date is the subject matter presented? 1 - Low/No
How adequate is the data presentation? N/A
Are units and terminology used correctly? N/A
Is the number of cases adequate? N/A
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 1 - Low/No
Please rate the practical significance. 1 - Low/No
Please rate the accuracy of methods. N/A
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 1 - Low/No
Please rate the appropriateness of the references. 4
Please evaluate the writing style and use of language. 3
Please judge the overall scientific quality of the manuscript. 1 - Low/No
Are you willing to review the revision of this manuscript? No: I have written in my first review that there is 
no need to publish AGAIN a previously published 
case report with no further information beside 
an extended follow-up. I am still this opinion. 
Even with the next and the next revision, there 
can‘t be any substantial changes and I don‘t 
think another review would help.
Comments to Authors:
I really appreciate the work of the group but there are still the same the images and tables as in the case report in 2015. I still don‘t see the 
necessity for publishing this report even if the follow-up is extended and the result is impressing.
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Reviewer 2: Klaus-Martin Schulte
Jul 30, 2017
Reviewer Recommendation Term: Accept
Overall Reviewer Manuscript Rating: 75
Custom Review Questions Response
Is the subject area appropriate for you? 3
Does the title clearly reflect the paper’s content? 4
Does the abstract clearly reflect the paper’s content? 5 - High/Yes
Do the keywords clearly reflect the paper’s content? 4
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 5 - High/Yes
How comprehensive and up-to-date is the subject matter presented? 5 - High/Yes
How adequate is the data presentation? 3
Are units and terminology used correctly? 4
Is the number of cases adequate? 3
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 4
Please rate the practical significance. 3
Please rate the accuracy of methods. 4
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 4
Please rate the appropriateness of the references. 5 - High/Yes
Please evaluate the writing style and use of language. 4
Please judge the overall scientific quality of the manuscript. 4
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
Dear Authors, 
thank you for taking the manuscript through the effort of review and making changes.  
I believe that the manuscript is well-written and clearly confers important long-term follow-up data in a rare but significant clinical scenario. 
Thank you
Editor-in-Chief’s Comments to Decision  
Aug 02, 2017
Dear Reader,
the manuscript “Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation for an advanced small intes-
tinal neuroendocrine neoplasm: an updated case report” by Ashley Kieran Clift was originally reviewed by two reviewers who recommended 
“revise with major modification” and “reject” respectively. According to the journal’s review policy we asked for a third reviewer who recom-
mended “accept with minor revision”. The revised manuscript was then sent to all three reviewers again, and one reviewer still argued for 
rejection. The main argument is, that in the revised manuscript “[…] there are still the same images and tables as in the case report in 2015. 
I still don’t see the necessity for publishing this report even if the follow-up is extended and the result is impressing”. Because the authors 
entitled the manuscript “[…] an updated case report”, the Editor-in-Chief decided to accept the manuscript for publication. We feel that the 
transparency of the peer-review process justifies this decision.
With best regards
Joachim Jaehne
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